We previously observed that RIG-I stimulation overcomes radiotherapy resistance in p53-positive melanoma, suggesting that RIG-I-driven innate immune activation in the tumor microenvironment might represent a general strategy to enhance various melanoma therapies.23 This evidence concerns the gene TP53 and melanoma.